121 related articles for article (PubMed ID: 6164559)
1. Selective enhancement of 5-fluorouridine uptake and action in rat hepatomas in vivo following pretreatment with D-galactosamine and 6-azauridine or N-(phosphonacetyl)-L-aspartate.
Anukarahanonta T; Holstege A; Keppler DO
Eur J Cancer (1965); 1980 Sep; 16(9):1171-80. PubMed ID: 6164559
[No Abstract] [Full Text] [Related]
2. Serum uridine levels in patients receiving N-(phosphonacetyl)-L-aspartate.
Karle JM; Anderson LW; Erlichman C; Cysyk RL
Cancer Res; 1980 Aug; 40(8 Pt 1):2938-40. PubMed ID: 7388844
[TBL] [Abstract][Full Text] [Related]
3. Effect of N-phosphonacetyl-L-aspartate and D-glucosamine on the incorporation of 5-fluorouridine into normal tissues and an adenocarcinoma in the rat.
Erichsen C; Christensson PI; Jakobsson B; Eriksson G; Yngner T; Jönsson PE; Stenram U
Anticancer Res; 1987; 7(1):77-80. PubMed ID: 3566186
[TBL] [Abstract][Full Text] [Related]
4. Response of psoriasis to N-phosphonacetyl-L-aspartate.
Earhart RH; DeConti RC; Rubin J; Ohnuma T
Lancet; 1981 Jun; 1(8232):1257-8. PubMed ID: 6112581
[No Abstract] [Full Text] [Related]
5. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
Grem JL; King SA; O'Dwyer PJ; Leyland-Jones B
Cancer Res; 1988 Aug; 48(16):4441-54. PubMed ID: 3293772
[No Abstract] [Full Text] [Related]
6. Effect of inhibitors of the de novo pyrimidine biosynthetic pathway on serum uridine levels in mice.
Karle JM; Anderson LW; Dietrick DD; Cysyk RL
Cancer Res; 1981 Dec; 41(12 Pt 1):4952-5. PubMed ID: 6171344
[TBL] [Abstract][Full Text] [Related]
7. Improved therapeutic index with sequential N-phosphonacetyl-L-aspartate plus high-dose methotrexate plus high-dose 5-fluorouracil and appropriate rescue.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
Cancer Res; 1983 Oct; 43(10):4653-61. PubMed ID: 6603903
[TBL] [Abstract][Full Text] [Related]
8. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
Carroll DS; Gralla RJ; Kemeny NE
Cancer Treat Rep; 1980; 64(2-3):349-51. PubMed ID: 7407769
[No Abstract] [Full Text] [Related]
9. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ; Kelsen DP; Houghton A; Golbey RB; Young CW
Cancer Treat Rep; 1980; 64(4-5):705-7. PubMed ID: 6448688
[No Abstract] [Full Text] [Related]
10. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
Johnson RK; Swyryd EA; Stark GR
Cancer Res; 1978 Feb; 38(2):371-8. PubMed ID: 620408
[No Abstract] [Full Text] [Related]
11. Depletion of blood plasma cytidine due to increased hepatocellular salvage in D-galactosamine-treated rats.
Holstege A; Manglitz D; Gerok W
Eur J Biochem; 1984 Jun; 141(2):339-44. PubMed ID: 6734601
[TBL] [Abstract][Full Text] [Related]
12. Increased formation of nucleotide derivatives of 5-fluorouridine in hepatoma cells treated with inhibitors of pyrimidine synthesis and D-galactosamine.
Holstege A; Herrmann B; Keppler DO
FEBS Lett; 1978 Nov; 95(2):361-5. PubMed ID: 720629
[No Abstract] [Full Text] [Related]
13. Inhibition by N-(phosphonacetyl)-L-aspartate of Ehrlich ascites tumour growth and glucose transport.
Leung SW; Fung KP; Choy YM; Lee CY
Cancer Lett; 1984 Jun; 23(2):183-8. PubMed ID: 6744243
[TBL] [Abstract][Full Text] [Related]
14. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
Grant S; Rauscher F; Jakubowski A; Cadman E
Cancer Res; 1981 Feb; 41(2):410-8. PubMed ID: 6160908
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
Jayaram HN; Cooney DA; Vistica DT; Kariya S; Johnson RK
Cancer Treat Rep; 1979 Aug; 63(8):1291-302. PubMed ID: 476706
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of 5-fluorouracil and N-(phosphonacetyl)-L-aspartate on cell growth and ribonucleic acid synthesis in human mammary carcinoma.
Ardalan B; Glazer RI; Kensler TW; Jayaram HN; Van Pham T; Macdonald JS; Cooney DA
Biochem Pharmacol; 1981 Aug; 30(15):2045-9. PubMed ID: 7295324
[No Abstract] [Full Text] [Related]
17. Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
Martin DS; Stolfi RL; Sawyer RC; Young CW
Cancer Treat Rep; 1985 Apr; 69(4):421-3. PubMed ID: 3888389
[No Abstract] [Full Text] [Related]
18. Selective inhibition of pyrimidine synthesis and depletion of nucleotide pools by N-(phosphonacetyl)-L-aspartate.
Moyer JD; Handschumacher RE
Cancer Res; 1979 Aug; 39(8):3089-94. PubMed ID: 455293
[No Abstract] [Full Text] [Related]
19. Treatment of psoriasis with N-phosphonacetyl-L-aspartate.
Doyle JA; Perry HO; Rubin J; Moertel CG
J Am Acad Dermatol; 1984 Jan; 10(1):21-4. PubMed ID: 6229552
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of antimetabolite action by uridylate trapping.
Keppler D; Holstege A; Weckbecker G; Fauler J; Gasser T
Adv Enzyme Regul; 1985; 24():417-27. PubMed ID: 3835824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
